文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Au 修饰的氧化铈纳米酶通过大大提高的酶活性和安全性来预防和治疗低氧诱导的肺动脉高压。

Au-modified ceria nanozyme prevents and treats hypoxia-induced pulmonary hypertension with greatly improved enzymatic activity and safety.

机构信息

Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), 13 Hangkong Road, Wuhan, 430030, China.

Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China.

出版信息

J Nanobiotechnology. 2024 Aug 19;22(1):492. doi: 10.1186/s12951-024-02738-4.


DOI:10.1186/s12951-024-02738-4
PMID:39160624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11331617/
Abstract

BACKGROUND: Despite recent advances the prognosis of pulmonary hypertension remains poor and warrants novel therapeutic options. Extensive studies, including ours, have revealed that hypoxia-induced pulmonary hypertension is associated with high oxidative stress. Cerium oxide nanozyme or nanoparticles (CeNPs) have displayed catalytic activity mimicking both catalase and superoxide dismutase functions and have been widely used as an anti-oxidative stress approach. However, whether CeNPs can attenuate hypoxia-induced pulmonary vascular oxidative stress and pulmonary hypertension is unknown. RESULTS: In this study, we designed a new ceria nanozyme or nanoparticle (AuCeNPs) exhibiting enhanced enzyme activity. The AuCeNPs significantly blunted the increase of reactive oxygen species and intracellular calcium concentration while limiting proliferation of pulmonary artery smooth muscle cells and pulmonary vasoconstriction in a model of hypoxia-induced pulmonary hypertension. In addition, the inhalation of nebulized AuCeNPs, but not CeNPs, not only prevented but also blunted hypoxia-induced pulmonary hypertension in rats. The benefits of AuCeNPs were associated with limited increase of intracellular calcium concentration as well as enhancement of extracellular calcium-sensing receptor (CaSR) activity and expression in rat pulmonary artery smooth muscle cells. Nebulised AuCeNPs showed a favorable safety profile, systemic arterial pressure, liver and kidney function, plasma Ca level, and blood biochemical parameters were not affected. CONCLUSION: We conclude that AuCeNPs is an improved reactive oxygen species scavenger that effectively prevents and treats hypoxia-induced pulmonary hypertension.

摘要

背景:尽管最近取得了进展,但肺动脉高压的预后仍然很差,需要新的治疗选择。包括我们在内的广泛研究表明,缺氧性肺动脉高压与高氧化应激有关。氧化铈纳米酶或纳米颗粒(CeNPs)具有模仿过氧化氢酶和超氧化物歧化酶功能的催化活性,已被广泛用作抗氧化应激方法。然而,CeNPs 是否可以减轻缺氧诱导的肺血管氧化应激和肺动脉高压尚不清楚。

结果:在这项研究中,我们设计了一种新型的氧化铈纳米酶或纳米颗粒(AuCeNPs),具有增强的酶活性。AuCeNPs 显著减轻了活性氧和细胞内钙浓度的增加,同时限制了缺氧性肺动脉高压模型中肺动脉平滑肌细胞的增殖和肺血管收缩。此外,雾化吸入 AuCeNPs 不仅可以预防,而且可以减轻缺氧诱导的大鼠肺动脉高压。AuCeNPs 的益处与细胞内钙浓度的增加有限以及大鼠肺动脉平滑肌细胞中细胞外钙敏感受体(CaSR)活性和表达的增强有关。雾化吸入 AuCeNPs 具有良好的安全性,全身动脉压、肝功能、肾功能、血浆 Ca 水平和血液生化参数不受影响。

结论:我们得出结论,AuCeNPs 是一种改良的活性氧清除剂,可有效预防和治疗缺氧性肺动脉高压。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/d17fad0f77e4/12951_2024_2738_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/de333c03d590/12951_2024_2738_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/44af9f5382a8/12951_2024_2738_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/15c1ab368848/12951_2024_2738_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/a2c316099254/12951_2024_2738_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/6b362a48b11d/12951_2024_2738_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/86cdac169a85/12951_2024_2738_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/d17fad0f77e4/12951_2024_2738_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/de333c03d590/12951_2024_2738_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/44af9f5382a8/12951_2024_2738_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/15c1ab368848/12951_2024_2738_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/a2c316099254/12951_2024_2738_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/6b362a48b11d/12951_2024_2738_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/86cdac169a85/12951_2024_2738_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd72/11331617/d17fad0f77e4/12951_2024_2738_Fig7_HTML.jpg

相似文献

[1]
Au-modified ceria nanozyme prevents and treats hypoxia-induced pulmonary hypertension with greatly improved enzymatic activity and safety.

J Nanobiotechnology. 2024-8-19

[2]
Notch activation of Ca-sensing receptor mediates hypoxia-induced pulmonary hypertension.

Hypertens Res. 2017-2

[3]
Enhanced Ca(2+)-sensing receptor function in idiopathic pulmonary arterial hypertension.

Circ Res. 2012-6-22

[4]
Extracellular calcium-sensing receptor is critical in hypoxic pulmonary vasoconstriction.

Antioxid Redox Signal. 2012-1-25

[5]
Chrysin Alleviates Chronic Hypoxia-Induced Pulmonary Hypertension by Reducing Intracellular Calcium Concentration in Pulmonary Arterial Smooth Muscle Cells.

J Cardiovasc Pharmacol. 2019-11

[6]
Prenatal hypoxia induced ETR activation and abnormal ROS signalling in pulmonary artery cells of rat offspring.

Reprod Toxicol. 2021-10

[7]
Hypoxia-Induced Mitogenic Factor Acts as a Nonclassical Ligand of Calcium-Sensing Receptor, Therapeutically Exploitable for Intermittent Hypoxia-Induced Pulmonary Hypertension.

Hypertension. 2017-5

[8]
Dihydropyridine Ca(2+) channel blockers increase cytosolic [Ca(2+)] by activating Ca(2+)-sensing receptors in pulmonary arterial smooth muscle cells.

Circ Res. 2013-1-8

[9]
Role of Transcription Factors in Pulmonary Artery Smooth Muscle Cells: An Important Link to Hypoxic Pulmonary Hypertension.

Adv Exp Med Biol. 2017

[10]
Pretreatment with the active fraction of Rhodiola tangutica (Maxim.) S.H. Fu rescues hypoxia-induced potassium channel inhibition in rat pulmonary artery smooth muscle cells.

J Ethnopharmacol. 2022-1-30

引用本文的文献

[1]
Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment.

Pharmaceutics. 2025-2-10

本文引用的文献

[1]
Synergistic cerium oxide nanozymes: targeting DNA damage and alleviating tumor hypoxia for improved NSCLC radiotherapy efficiency.

J Nanobiotechnology. 2024-1-10

[2]
Multienzyme-Like Nanozymes: Regulation, Rational Design, and Application.

Adv Mater. 2024-3

[3]
Gold nanoparticles-embedded ceria with enhanced antioxidant activities for treating inflammatory bowel disease.

Bioact Mater. 2023-1-26

[4]
Cerium oxide nanoparticles with antioxidative neurorestoration for ischemic stroke.

Biomaterials. 2022-12

[5]
Orally-administrated mitochondria attenuate pulmonary hypertension with the aid of erythrocytes as carriers.

Clin Transl Med. 2022-9

[6]
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

Eur Heart J. 2022-10-11

[7]
The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.

Circ Res. 2022-4-29

[8]
Endothelial Senescence: A New Age in Pulmonary Hypertension.

Circ Res. 2022-3-18

[9]
Peptide Blocking Self-Polymerization of Extracellular Calcium-Sensing Receptor Attenuates Hypoxia-Induced Pulmonary Hypertension.

Hypertension. 2021-11

[10]
Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension.

Circulation. 2021-5-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索